Chen M, Yang Z D, Smith K M, Carter J D, Nadler J L
Department of Medicine, Division of Endocrinology and Metabolism, School of Medicine, University of Virginia, PO Box 801405, Charlottesville, VA, 22908-1405, USA.
Diabetologia. 2005 Mar;48(3):486-95. doi: 10.1007/s00125-005-1673-y. Epub 2005 Feb 24.
AIMS/HYPOTHESIS: Beta cell inflammation and cytokine-induced toxicity are central to autoimmune diabetes development. Lipid mediators generated upon lipoxygenase (LO) activation can participate in inflammatory pathways. 12LO-deficient mice are resistant to streptozotocin-induced diabetes. This study sought to characterise the cellular processes involving 12LO-activation lipid inflammatory mediator production in cytokine-treated pancreatic beta cells.
Islets and beta cell lines were treated with a combination of IL-1beta, IFN-gamma and TNF-alpha, or the 12LO product 12(S)-hydroxyeicosatetraenoic acid (HETE). Insulin secretion was measured using an enzyme immunoassay, and cell viability was evaluated using an in situ terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling assay. 12LO activity was evaluated and 12LO protein levels were determined using immunoblotting with a selective leucocyte type 12LO antibody. Cellular localisation of 12LO was evaluated using immunocytochemistry.
Basal expression of leucocyte type 12LO protein was found in human and mouse islets and in several rodent beta cell lines. In mouse beta-TC3 cells, and in human islets, cytokines induced release of 12-HETE within 30 min. Cytokine addition also induced a rapid translocation of 12LO protein from the cytosol to the nucleus of beta-TC3 cells as shown by subcellular fractionation and immunostaining. Cytokine-induced cell death and inhibition of insulin secretion were partially reversed by baicalein, a 12LO inhibitor. 12(S)-HETE inhibited beta-TC3 cell insulin release in a time- and concentration-dependent manner. Incubating beta-TC3 cells with 100 nmol/l of 12(S)-HETE resulted in a 57% reduction in basal insulin release (6 h), and a 17% increase in cell death (18 h) as compared with untreated cells. 12(S)-HETE activated the stress-activated protein kinase c-Jun N-terminal kinase and p38 within 15 min, as judged by increased kinase protein phosphorylation.
CONCLUSIONS/INTERPRETATION: The data suggest that inflammatory cytokines rapidly activate 12LO and show for the first time that cytokines induce 12LO translocation. The effects of 12-HETE on insulin secretion, cytotoxicity and kinase activation were similar to the effects seen with cytokines. The results provide mechanistic information of cytokine-induced toxic effects on pancreatic beta cells and support the hypothesis that blocking 12LO activation could provide a new therapeutic way to protect pancreatic beta cells from autoimmune injury.
目的/假设:β细胞炎症和细胞因子诱导的毒性是自身免疫性糖尿病发展的核心。脂氧合酶(LO)激活后产生的脂质介质可参与炎症途径。12-LO缺陷小鼠对链脲佐菌素诱导的糖尿病具有抗性。本研究旨在表征细胞因子处理的胰腺β细胞中涉及12-LO激活、脂质炎症介质产生的细胞过程。
胰岛和β细胞系用白细胞介素-1β、干扰素-γ和肿瘤坏死因子-α的组合,或12-LO产物12(S)-羟基二十碳四烯酸(HETE)处理。使用酶免疫测定法测量胰岛素分泌,并使用原位末端脱氧核苷酸转移酶介导的dUTP缺口末端标记测定法评估细胞活力。使用选择性白细胞型12-LO抗体进行免疫印迹评估12-LO活性并测定12-LO蛋白水平。使用免疫细胞化学评估12-LO的细胞定位。
在人和小鼠胰岛以及几种啮齿动物β细胞系中发现白细胞型12-LO蛋白的基础表达。在小鼠β-TC3细胞和人胰岛中,细胞因子在30分钟内诱导12-HETE释放。如亚细胞分级分离和免疫染色所示,添加细胞因子还诱导12-LO蛋白从β-TC3细胞的细胞质快速转运至细胞核。12-LO抑制剂黄芩苷部分逆转了细胞因子诱导的细胞死亡和胰岛素分泌抑制。12(S)-HETE以时间和浓度依赖性方式抑制β-TC3细胞胰岛素释放。与未处理的细胞相比,用100 nmol/l的12(S)-HETE孵育β-TC3细胞导致基础胰岛素释放降低57%(6小时),细胞死亡增加17%(18小时)。12(S)-HETE在15分钟内激活应激激活蛋白激酶c-Jun N末端激酶和p38,通过激酶蛋白磷酸化增加判断。
结论/解读:数据表明炎症细胞因子迅速激活12-LO,并首次表明细胞因子诱导12-LO易位。12-HETE对胰岛素分泌、细胞毒性和激酶激活的影响与细胞因子所见的影响相似。结果提供了细胞因子诱导的对胰腺β细胞毒性作用的机制信息,并支持阻断12-LO激活可提供一种保护胰腺β细胞免受自身免疫损伤的新治疗方法的假设。